Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Ronald de Wit

Showing results (51-60 of 204) with videos related to

Pageof 21
Sort By:
Ebiomedicine|December 26, 2017
Testosterone Diminishes Cabazitaxel Efficacy and Intratumoral Accumulation in a Prostate Cancer Xenograft ModelLisanne Mout, Ronald de Wit, Debra Stuurman, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|November 3, 2007
A contemporary prognostic nomogram for men with hormone-refractory metastatic prostate cancer: a TAX327 study analysisAndrew J Armstrong, Elizabeth S Garrett-Mayer, Yi-Chun Ou Yang, et al.
European Urology|November 13, 2007
Noninvasive detection of testicular carcinoma in situ in semen using OCT3/4Niels J van Casteren, Hans Stoop, Gert R Dohle, et al.
European Urology|August 21, 2013
Initial biopsy Gleason score as a predictive marker for survival benefit in patients with castration-resistant prostate cancer treated with docetaxel: data from the TAX327 studyRobert J van Soest, Ellen S de Morrée, Liji Shen, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 2, 2018
Controversies in the Management of Clinical Stage I Seminoma: Carboplatin a Decade in-Time to Start Backing OutRune A W van de Wetering, Stefan Sleijfer, Darren R Feldman, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 1, 2007
Prostate-specific antigen and pain surrogacy analysis in metastatic hormone-refractory prostate cancerAndrew J Armstrong, Elizabeth Garrett-Mayer, Yi-Chun Ou Yang, et al.
Cancer|March 3, 2011
The association between radiographic response and overall survival in men with metastatic castration-resistant prostate cancer receiving chemotherapyGuru Sonpavde, Gregory R Pond, William R Berry, et al.
Urologic Oncology|October 5, 2010
Serum alkaline phosphatase changes predict survival independent of PSA changes in men with castration-resistant prostate cancer and bone metastasis receiving chemotherapyGuru Sonpavde, Gregory R Pond, William R Berry, et al.
Cancers|April 3, 2021
Pain Progression at Initiation of Cabazitaxel in Metastatic Castration-Resistant Prostate Cancer (mCRPC): A Post Hoc Analysis of the PROSELICA StudyNicolas Delanoy, Debbie Robbrecht, Mario Eisenberger, et al.
European Journal of Cancer (Oxford, England : 1990)|February 2, 2016
Severe neutropenia during cabazitaxel treatment is associated with survival benefit in men with metastatic castration-resistant prostate cancer (mCRPC): A post-hoc analysis of the TROPIC phase III trialAlexander Meisel, Stefanie von Felten, Deborah R Vogt, et al.
Pageof 21

Showing results (51-60 of 204) with videos related to

Sort By:
Pageof 21
Ebiomedicine|December 26, 2017
Testosterone Diminishes Cabazitaxel Efficacy and Intratumoral Accumulation in a Prostate Cancer Xenograft ModelLisanne Mout, Ronald de Wit, Debra Stuurman, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|November 3, 2007
A contemporary prognostic nomogram for men with hormone-refractory metastatic prostate cancer: a TAX327 study analysisAndrew J Armstrong, Elizabeth S Garrett-Mayer, Yi-Chun Ou Yang, et al.
European Urology|November 13, 2007
Noninvasive detection of testicular carcinoma in situ in semen using OCT3/4Niels J van Casteren, Hans Stoop, Gert R Dohle, et al.
European Urology|August 21, 2013
Initial biopsy Gleason score as a predictive marker for survival benefit in patients with castration-resistant prostate cancer treated with docetaxel: data from the TAX327 studyRobert J van Soest, Ellen S de Morrée, Liji Shen, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 2, 2018
Controversies in the Management of Clinical Stage I Seminoma: Carboplatin a Decade in-Time to Start Backing OutRune A W van de Wetering, Stefan Sleijfer, Darren R Feldman, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 1, 2007
Prostate-specific antigen and pain surrogacy analysis in metastatic hormone-refractory prostate cancerAndrew J Armstrong, Elizabeth Garrett-Mayer, Yi-Chun Ou Yang, et al.
Cancer|March 3, 2011
The association between radiographic response and overall survival in men with metastatic castration-resistant prostate cancer receiving chemotherapyGuru Sonpavde, Gregory R Pond, William R Berry, et al.
Urologic Oncology|October 5, 2010
Serum alkaline phosphatase changes predict survival independent of PSA changes in men with castration-resistant prostate cancer and bone metastasis receiving chemotherapyGuru Sonpavde, Gregory R Pond, William R Berry, et al.
Cancers|April 3, 2021
Pain Progression at Initiation of Cabazitaxel in Metastatic Castration-Resistant Prostate Cancer (mCRPC): A Post Hoc Analysis of the PROSELICA StudyNicolas Delanoy, Debbie Robbrecht, Mario Eisenberger, et al.
European Journal of Cancer (Oxford, England : 1990)|February 2, 2016
Severe neutropenia during cabazitaxel treatment is associated with survival benefit in men with metastatic castration-resistant prostate cancer (mCRPC): A post-hoc analysis of the TROPIC phase III trialAlexander Meisel, Stefanie von Felten, Deborah R Vogt, et al.
Pageof 21